Back to Search
Start Over
Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs.
- Source :
-
European journal of pharmacology [Eur J Pharmacol] 2015 Sep 05; Vol. 762, pp. 364-71. Date of Electronic Publication: 2015 Jun 06. - Publication Year :
- 2015
-
Abstract
- Angiotensin II-receptor blockers (ARBs), similar to HMG-CoA reductase inhibitors (statins), could improve lipid metabolism abnormalities. There might be some cross-talking pathways between statins and ARBs to produce additive beneficial effects on lipid metabolism in dyslipidemia. However, few studies investigate the effects of ARBs on the therapeutic efficacy of statins in dyslipidemia. The present study was designed to systematically evaluate the effects of telmisartan on the therapeutic efficacy of pitavastatin on lowering lipid level and reducing fat deposition by employing a dyslipidemia model, guinea pigs. 48 Male guinea pigs fed with high-fat diet were randomly grouped and treated with vehicle, telmisartan, pitavastatin or telmisartan/pitavastatin combinations. After treatment for eight weeks, telmisartan could significantly enhance the therapeutic efficacy of pitavastatin by extremely reducing body weight gain, weight of adipose tissue and adipocyte size. However, telmisartan/pitavastatin combinations could not further improve lipid levels on the basis of pitavastain, though single telmisartan markedly decreased triglyceride (TG) and slightly increased high density lipoprotein cholesterol (HDL-C). Moreover, telmisartan/pitavastatin combinations significantly upregulated the gene expression level of peroxisome proliferator-activated receptor (PPAR)-δ, but no effects on the expression of PPAR-α/γ, leptin and adiponectin compared to monotherapy. Taken together, our studies provided new evidences that telmisartan has an additive beneficial influence on decreasing fat deposition and weight gain through PPAR-δ pathway but cannot enhance the therapeutic efficacy of pitavastatin on lowering lipid levels. The combinational administration of telmisartan and pitavastatin could be a potential therapeutic strategy for dyslipidemia related obesity and worthy of further investigation in obese animal models.<br /> (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Subjects :
- Adipocytes drug effects
Angiotensin II Type 1 Receptor Blockers therapeutic use
Animals
Benzimidazoles therapeutic use
Benzoates therapeutic use
Body Weight drug effects
Drug Interactions
Dyslipidemias metabolism
Dyslipidemias pathology
Gene Expression Regulation drug effects
Guinea Pigs
Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology
Lipids blood
Liver drug effects
Liver metabolism
Male
Quinolines therapeutic use
Telmisartan
Angiotensin II Type 1 Receptor Blockers pharmacology
Benzimidazoles pharmacology
Benzoates pharmacology
Diet, High-Fat adverse effects
Dyslipidemias chemically induced
Dyslipidemias drug therapy
Quinolines pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0712
- Volume :
- 762
- Database :
- MEDLINE
- Journal :
- European journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 26057693
- Full Text :
- https://doi.org/10.1016/j.ejphar.2015.06.005